Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers

Table 2 BRCA2 group and IHC tumour characteristics.

ID pts	Age at diagnosis	DNA	Mutation effect	Grade	° ER (score)	° PR (score)	§HER2	^ BRCAPRO BRCA1	^ BRCAPRO BRCA2	^ BRCAPRO total	*BC, CBC and BBC cases	*OC cases
BR288	36	9326insA	3043X	3	+ (6)	+ (5)	1+	0.003	0.026	0.029	/	1 (44)
BR295	54	657insC	157X	2	+ (8)	+ (5)	-	0.029	0.405	0.434	2 (41+43 CBC, 48)	/
BR312	47	IVS16-2A>G	Exon skipping	3	+ (5)	+ (3)	1+	0.002	0.365	0.367	2 (47, 77 M)	/
BR342	44+52 CBC	9106C>T	Q2960X	3	+ (8)	+ (3)	2+	0.006	0.182	0.187	2 (59, 68+75 CBC)	/
BR360	43	IVS23+1G>T	Exon skipping	3	+ (4)	+ (6)	2+/3+	0.088	0.553	0.640	1 (30 BBC)	/
BR382	44+63 CBC	7507del7	2168X	3	+ (6)	+ (8)	1+	0.002	0.061	0.063	1 (35)	/
BR410	24	9325delA	3061X	2	+ (7)	+ (4)	1+	0.170	0.557	0.727	1 (47)	2 (54, 73)
BR450	48	4450C>T	Q1408X	1	+ (7)	+ (7)	-	0.010	0.044	0.054	2 (52, 55)	2 (38, 55)
BR571	31	3036del4	959X	2	+ (3)	+ (6)	3+	0.001	0.037	0.038	3 (50, 50, 61)	/

BC = breast cancer; CBC = controlateral breast cancer; BBC = bilateral breast cancer; OC = ovarian cancer; / = no cases; M = male. ° IHC Allred total scores of 3 or more were reported as positive. §HER2 IHC scores: - negative, 1+ weak, 2+ moderate, 3+ strong. ^ Probability of mutation calculated by BRCAPRO Software http://www.isds.duke.edu/~gp/brcapro.html; * number of additional tumours in the family and ages of onset in parentheses.